Sana Biotechnology, Inc. Asset Impairment Charges
Sana Biotechnology, Inc. (SANA) reported Asset Impairment Charges of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetImpairmentCharges · last filed 2026-08-10
- Sana Biotechnology, Inc. asset impairment charges for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Sana Biotechnology, Inc. asset impairment charges for the quarter ending 2025-12-31 was $0.00.
- Sana Biotechnology, Inc. asset impairment charges for the quarter ending 2025-09-30 was $0.00.
- Sana Biotechnology, Inc. asset impairment charges for the quarter ending 2025-06-30 was $44.61M.
- Sana Biotechnology, Inc. asset impairment charges for fiscal 2025 was $44.61M, a 2259.12% increase from fiscal 2024.
- Sana Biotechnology, Inc. asset impairment charges for fiscal 2024 was $1.89M, a 73.04% decline from fiscal 2023.
- Sana Biotechnology, Inc. asset impairment charges for fiscal 2023 was $7.01M.
| Period end | Asset Impairment Charges 3 month | Asset Impairment Charges 6 month | Asset Impairment Charges 9 month | Asset Impairment Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $44.61M derived: sum of 3 quarters · filed 2026-08-10 | $44.61M 10-K · filed 2026-03-03 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $44.61M derived: sum of 2 quarters · filed 2026-08-10 | $44.61M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $44.61M 10-Q · filed 2026-08-10 | $44.61M 10-Q · filed 2026-08-10 | ||
| 2024-12-31 | $1.89M 10-K · filed 2026-03-03 | |||
| 2023-12-31 | $7.01M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |